Literature DB >> 8387267

Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase.

J E Souness1, L C Scott.   

Abstract

The stereospecificity of rolipram inhibition of particulate cyclic AMP-specific phosphodiesterase (PDE IV) from guinea-pig eosinophils has been investigated. (-)-Rolipram (IC50 = 0.22 +/- 0.08 microM) was 2.5-fold more potent than (+)-rolipram (IC50 = 0.58 +/- 0.05 microM) in inhibiting membrane-bound PDE IV. Solubilization of PDE IV with deoxycholate (0.5%) and NaCl (100 mM) increased rolipram stereospecificity [IC50 (-)-rolipram = 0.020 +/- 0.002 microM; IC50 (+)-rolipram = 0.33 +/- 0.07 microM]. Partial purification of this solubilized PDE IV by DEAE-trisacryl anion-exchange chromatography reduced the enantiomeric potency difference compared with the pre-chromatographed activity, with (-)-rolipram (IC50 = 0.20 +/- 0.02 microM) being only 2.9-fold more potent than (+)-rolipram (IC50 = 0.57 +/- 0.14 microM). Vanadate-glutathione complex (V-GSH) stimulated membrane-bound PDE IV activity and increased the potency of (-)-rolipram (IC50 = 0.014 +/- 0.006 microM) but not (+)-rolipram (IC50 = 0.32 +/- 0.07 microM). In intact eosinophils, (-)-rolipram (EC50 = 0.19 +/- 0.02 microM) was 10-fold more potent than (+)-rolipram (EC50 = 1.87 +/- 0.09 microM) in enhancing isoprenaline (10 microM)-stimulated cyclic AMP accumulation. Strong correlations were demonstrated for displacement of [3H]rolipram binding to brain membranes by several PDE inhibitors and their inhibition of solubilized PDE IV (r = 0.98, P < 0.001, n = 7) and stimulation of cyclic AMP accumulation in intact cells (r = 0.98, P < 0.001, n = 6). Rolipram was a relatively weak inhibitor of partially purified pig aortic PDE IV and only slight stereospecificity was exhibited [IC50 (-)-rolipram = 1.47 +/- 0.09 microM; IC50 (+)-rolipram = 2.73 +/- 0.38 microM]. The results indicate the presence of a partially concealed stereospecific site (Sr) on eosinophil PDE IV possibly similar to the high-affinity rolipram-binding site in brain through which rolipram can potently inhibit enzyme activity. This site, which apparently is not present on partially purified pig aortic PDE IV, is concealed in freshly prepared eosinophil membranes but is exposed by solubilization or V-GSH treatment and is important in regulating intracellular cyclic AMP accumulation in intact cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387267      PMCID: PMC1132537          DOI: 10.1042/bj2910389

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase.

Authors:  R Schmiechen; H H Schneider; H Wachtel
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 2.  Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Authors:  J A Beavo; D H Reifsnyder
Journal:  Trends Pharmacol Sci       Date:  1990-04       Impact factor: 14.819

3.  Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle.

Authors:  T J Torphy; L B Cieslinski
Journal:  Mol Pharmacol       Date:  1990-02       Impact factor: 4.436

4.  Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes beta-adrenoceptor subsensitivity in rat cerebral cortex.

Authors:  J E Schultz; B H Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-05       Impact factor: 3.000

5.  Stereospecific binding of the antidepressant rolipram to brain protein structures.

Authors:  H H Schneider; R Schmiechen; M Brezinski; J Seidler
Journal:  Eur J Pharmacol       Date:  1986-08-07       Impact factor: 4.432

6.  Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase.

Authors:  G P Livi; P Kmetz; M M McHale; L B Cieslinski; G M Sathe; D P Taylor; R L Davis; T J Torphy; J M Balcarek
Journal:  Mol Cell Biol       Date:  1990-06       Impact factor: 4.272

7.  Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram.

Authors:  P Kaulen; G Brüning; H H Schneider; M Sarter; H G Baumgarten
Journal:  Brain Res       Date:  1989-12-04       Impact factor: 3.252

8.  Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig.

Authors:  A L Harris; M J Connell; E W Ferguson; A M Wallace; R J Gordon; E D Pagani; P J Silver
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

9.  Pharmacokinetics of (+)-rolipram and (-)-rolipram in healthy volunteers.

Authors:  W Krause; G Kühne; N Sauerbrey
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 10.  Unusual stereospecificity of the potential antidepressant rolipram on the cyclic AMP generating system from rat brain cortex.

Authors:  J E Schultz; G Folkers
Journal:  Pharmacopsychiatry       Date:  1988-03       Impact factor: 5.788

View more
  10 in total

1.  Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.

Authors:  I McPhee; L Pooley; M Lobban; G Bolger; M D Houslay
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

2.  Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.

Authors:  J E Souness; M Griffin; C Maslen; K Ebsworth; L C Scott; K Pollock; M N Palfreyman; J A Karlsson
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

Authors:  M M Teixeira; A G Rossi; M A Giembycz; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.

Authors:  J J Kelly; P J Barnes; M A Giembycz
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

5.  Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.

Authors:  R J Owens; C Catterall; D Batty; J Jappy; A Russell; B Smith; J O'Connell; M J Perry
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

6.  Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.

Authors:  J E Souness; M E Villamil; L C Scott; A Tomkinson; M A Giembycz; D Raeburn
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.

Authors:  J E Souness; C Maslen; S Webber; M Foster; D Raeburn; M N Palfreyman; M J Ashton; J A Karlsson
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 8.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

Authors:  R Hoffmann; I R Wilkinson; J F McCallum; P Engels; M D Houslay
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

10.  Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient.

Authors:  Donna M Cartledge; Katherine M Robbins; Katherine M Drake; Rachel Sternberg; Deborah L Stabley; Karen W Gripp; E Anders Kolb; Katia Sol-Church; Andrew D Napper
Journal:  Front Oncol       Date:  2017-04-03       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.